Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Bayer Schering Pharma commences new cancer drug trial

Bayer Schering Pharma commences new cancer drug trial

10th May 2010

Bayer Schering Pharma has initiated a new phase III clinical trial of regorafenib, an investigational treatment for metastatic colorectal cancer.

The pharmaceutical company has begun to enrol patients for the international multicentre Correct study, with approximately 690 cancer sufferers set to take part in total.

This trial is designed to gauge the effectiveness of regorafenib in terms of progression-free survival, tumour response rate and safety when compared to a placebo control group.

Dr Kemal Malik, head of global development at Bayer Schering Pharma, said this drug could potentially address the unmet needs of patients who have proven unresponsive to other treatments.

He said: “The initiation of a Phase III clinical trial for regorafenib marks the starting point for a potential new treatment option for colorectal cancer patients.”

Last month, the Bayer group published its financial report for the first quarter of 2010, during which its sales increased by 5.3 per cent year-on-year.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.